Hyderabad-based biopharmaceutical company Suven Life Sciences Limited (Suven) stated that it has secured three patents, two from the US and one from Mexico, for its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2025 and 2028.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents that are useful in the treatment of cognitive impairment associated with disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With the new patents, Suven has a total of 11 patents from the US and 12 patents from Mexico.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally,” chief executive officer of the company, Venkat Jasti, stated in a press release on Tuesday.
